Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Accepted author manuscript, 3.12 MB, PDF document

  • Chiara Raggi
  • Maria Letizia Taddei
  • Elena Sacco
  • Nadia Navari
  • Margherita Correnti
  • Benedetta Piombanti
  • Mirella Pastore
  • Claudia Campani
  • Erica Pranzini
  • Jessica Iorio
  • Giulia Lori
  • Tiziano Lottini
  • Clelia Peano
  • Javier Cibella
  • Luca di Tommaso
  • Luca Viganò
  • Giovanni Di Maira
  • Stefania Madiai
  • Matteo Ramazzotti
  • Ivan Orlandi
  • Annarosa Arcangeli
  • Paola Chiarugi
  • Fabio Marra

BACKGROUND & AIMS: Little is known about the metabolic regulation of cancer stem cells (CSCs) in cholangiocarcinoma (CCA). We analyzed whether mitochondrial-dependent metabolism and related signaling pathways contribute to stemness in CCA.

METHODS: The stem-like subset was enriched by sphere culture (SPH) in human intrahepatic CCA cells (HUCCT1 and CCLP1) and compared to cells cultured in monolayer. Extracellular flux analysis was examined by Seahorse technology and high-resolution respirometry. In patients with CCA, expression of factors related to mitochondrial metabolism was analyzed for possible correlation with clinical parameters.

RESULTS: Metabolic analyses revealed a more efficient respiratory phenotype in CCA-SPH than in monolayers, due to mitochondrial oxidative phosphorylation. CCA-SPH showed high mitochondrial membrane potential and elevated mitochondrial mass, and over-expressed peroxisome proliferator-activated receptor gamma coactivator (PGC)-1α, a master regulator of mitochondrial biogenesis. Targeting mitochondrial complex I in CCA-SPH using metformin, or PGC-1α silencing or pharmacologic inhibition (SR-18292), impaired spherogenicity and expression of markers related to the CSC phenotype, pluripotency, and epithelial-mesenchymal transition. In mice with tumor xenografts generated by injection of CCA-SPH, administration of metformin or SR-18292 significantly reduced tumor growth and determined a phenotype more similar to tumors originated from cells grown in monolayer. In patients with CCA, expression of PGC-1α correlated with expression of mitochondrial complex II and of stem-like genes. Patients with higher PGC-1α expression by immunostaining had lower overall and progression-free survival, increased angioinvasion and faster recurrence. In GSEA analysis, patients with CCA and high levels of mitochondrial complex II had shorter overall survival and time to recurrence.

CONCLUSIONS: The CCA stem-subset has a more efficient respiratory phenotype and depends on mitochondrial oxidative metabolism and PGC-1α to maintain CSC features.

LAY SUMMARY: The growth of many cancers is sustained by a specific type of cells with more embryonic characteristics, termed 'cancer stem cells'. These cells have been described in cholangiocarcinoma, a type of liver cancer with poor prognosis and limited therapeutic approaches. We demonstrate that cancer stem cells in cholangiocarcinoma have different metabolic features, and use mitochondria, an organelle located within the cells, as the major source of energy. We also identify PGC-1α, a molecule which regulates the biology of mitochondria, as a possible new target to be explored for developing new treatments for cholangiocarcinoma.

Original languageEnglish
JournalJournal of Hepatology
Volume74
Issue number6
Pages (from-to)1373-1385
Number of pages13
ISSN0169-5185
DOIs
Publication statusPublished - 2021

Bibliographical note

Copyright © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

    Research areas

  • Animals, Bile Duct Neoplasms/drug therapy, Carcinogenesis/drug effects, Cell Line, Tumor, Cholangiocarcinoma/drug therapy, Electron Transport Complex II/metabolism, Epithelial-Mesenchymal Transition/drug effects, Gene Silencing, Humans, Indoles/administration & dosage, Male, Metformin/administration & dosage, Mice, Mice, Inbred NOD, Mice, SCID, Mitochondria/metabolism, Neoplastic Stem Cells/metabolism, Oxidative Phosphorylation/drug effects, Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/antagonists & inhibitors, Phenotype, Progression-Free Survival, Propanols/administration & dosage, Signal Transduction/drug effects, Transfection, Treatment Outcome, Tumor Burden/drug effects, Xenograft Model Antitumor Assays

ID: 300770312